Previous 10 | Next 10 |
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clini...
Celsion Corporation (NASDAQ:CLSN +11.5%) stock jumps after H.C. Wainwright analyst Emily Bodnar initiates coverage on the stock with a Buy rating and a price target of $16, implies a 360% increase from last price. The company is developing its novel DNA-based pla...
Antares Pharma ATRS +49% on ~$1B acquisition deal by Halozyme. Sierra Oncology SRRA +37% GSK to acquire Sierra Oncology for $1.9B to bolster specialty meds. BriaCell Therapeutics (BCTX) +17% receives FDA fast track approval for targeted breast cancer immunotherapy. Hi...
LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the Wo...
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 1,328,27...
Gainers: Advent Technologies (ADN) +79%. Tufin Software Technologies (TUFN) +43%. Mobiquity Technologies (OTCQB:MOBQ) +30%. Missfresh (MF) +25%. Venator Materials (VNTR) +17%. Team (TISI) +16%. Concord Medical Services (CCM) +15%. NextDecade (NEXT) +15%. Smart Sand (SND) +13%. ...
Gainers: Tilray Brands (TLRY) +15%. Clever Leaves (CLVR) +12%. Ensysce Biosciences (ENSC) +11%. Icosavax (ICVX) +10%. Cullinan Oncology (CGEM) +6%. Losers: Celsion (CLSN) -19%. IMARA (IMRA) -14%. Owlet (OWLT) -12%. PAVmed (PAVM) -10%. Accelerate Diagnos...
Clinical-stage biotech, Celsion Corporation (NASDAQ:CLSN) has crashed ~19% in the pre-market Wednesday after announcing a direct offering of its common stock for $7.0 million gross proceeds. The company said that it reached definitive agreements with institutional investors to purch...
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Cor...
LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shar...
News, Short Squeeze, Breakout and More Instantly...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...